Your browser doesn't support javascript.
loading
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
Neumann, Ulf; Ufer, Mike; Jacobson, Laura H; Rouzade-Dominguez, Marie-Laure; Huledal, Gunilla; Kolly, Carine; Lüönd, Rainer M; Machauer, Rainer; Veenstra, Siem J; Hurth, Konstanze; Rueeger, Heinrich; Tintelnot-Blomley, Marina; Staufenbiel, Matthias; Shimshek, Derya R; Perrot, Ludovic; Frieauff, Wilfried; Dubost, Valerie; Schiller, Hilmar; Vogg, Barbara; Beltz, Karen; Avrameas, Alexandre; Kretz, Sandrine; Pezous, Nicole; Rondeau, Jean-Michel; Beckmann, Nicolau; Hartmann, Andreas; Vormfelde, Stefan; David, Olivier J; Galli, Bruno; Ramos, Rita; Graf, Ana; Lopez Lopez, Cristina.
  • Neumann U; Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland ulf.neumann@novartis.com cristina.lopez_lopez@novartis.com.
  • Ufer M; Translational Medicine, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Jacobson LH; Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Rouzade-Dominguez ML; Translational Medicine, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Huledal G; PK Sciences, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Kolly C; Preclinical Safety, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Lüönd RM; Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Machauer R; Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Veenstra SJ; Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Hurth K; Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Rueeger H; Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Tintelnot-Blomley M; Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Staufenbiel M; Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Shimshek DR; Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Perrot L; Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Frieauff W; Preclinical Safety, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Dubost V; Preclinical Safety, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Schiller H; PK Sciences, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Vogg B; PK Sciences, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Beltz K; PK Sciences, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Avrameas A; Biomarker Discovery, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Kretz S; Biomarker Discovery, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Pezous N; Translational Medicine, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Rondeau JM; Chemical Biology and Therapeutics, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Beckmann N; Musculoskeletal Diseases, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Hartmann A; Preclinical Safety, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • Vormfelde S; Translational Medicine, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • David OJ; Global Drug Development, Novartis, Basel, Switzerland.
  • Galli B; Global Drug Development, Novartis, Basel, Switzerland.
  • Ramos R; Global Drug Development, Novartis, Basel, Switzerland.
  • Graf A; Global Drug Development, Novartis, Basel, Switzerland.
  • Lopez Lopez C; Global Drug Development, Novartis, Basel, Switzerland ulf.neumann@novartis.com cristina.lopez_lopez@novartis.com.
EMBO Mol Med ; 10(11)2018 11.
Article en En | MEDLINE | ID: mdl-30224383
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxazinas / Ácido Aspártico Endopeptidasas / Secretasas de la Proteína Precursora del Amiloide / Enfermedad de Alzheimer Tipo de estudio: Clinical_trials Límite: Animals / Female / Humans / Male Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxazinas / Ácido Aspártico Endopeptidasas / Secretasas de la Proteína Precursora del Amiloide / Enfermedad de Alzheimer Tipo de estudio: Clinical_trials Límite: Animals / Female / Humans / Male Idioma: En Año: 2018 Tipo del documento: Article